If you enjoy this content, please share it with a colleague
RELATED CONTENT
September 21, 2009 – IBA (Ion Beam Applications S.A.), a provider of PET radiopharmaceuticals, and Aposense Ltd., a developer of agents targeting apoptosis (programmed cell death) for molecular imaging and therapy, today announced an exclusive collaboration agreement for commercializing Aposense [18F]–ML-10, Aposense’s novel agent for molecular imaging of apoptosis.
February 23, 2009 - An advance in the way protons are delivered at the University of Florida Proton Therapy Institute — called uniform scanning — reportedly enable physicians to treat tumors that are deeper in the body, tumors that are very large and tumors that are situated closer to vital organs.
December 23, 2008 - The FDA cleared Ion Beam Applications’ (IBA) cyclotron-based integrated commercial proton therapy system with pencil beam scanning (PBS), a delivery method that allows for precise dose delivery by its proton therapy system.
July 25, 2007 – The IBA business unit, IBA Particle Therapy, recently announced the release of its full-size Universal Nozzle alpha that reportedly allows treatment planners and clinicians to expand capabilities in choosing the optimal treatment beam delivery mode for each patient.
July 25, 2007 – The IBA business unit, IBA Particle Therapy, recently announced the release of its full-size Universal ...